Epinephrine Injection Drug Shortage Impacts Medicaid Non-Preferred Status

Mylan issued an alert on February 07, 2020, regarding the manufacturing challenges in the production of EpiPen (epinephrine injection, USP) 0.3 mg and EpiPen Jr (Epinephrine Injection, USP) 0.15 mg auto-injectors and the authorized generic versions of these strengths. These challenges resulted in the reduced availability of these product.

VDP temporarily removed the non-preferred status from the following:

NDC	Name
00093598627	Epinephrine 0.3 mg auto-injector

This change will allow providers to prescribe these product NDCs without requiring non-preferred prior authorization and allow continued access to medication. The current preferred NDCs are:

NDC	Name
00093598527	Epinephrine 0.15 mg auto-injector
00115169449	Epinephrine 0.3 mg auto-injector
00115169549	Epinephrine 0.15 mg auto-injector
49502010101	Epinephrine 0.15 Mg auto-injector
49502010102	Epinephrine 0.15 Mg auto-injector
49502010201	Epinephrine 0.3 Mg auto-injector
49502010202	Epinephrine 0.3 Mg auto-injector

This is a temporary change until the preferred products are sufficiently available again in the market. VDP confirmed there may be outages varying between pharmacies despite Mylan products no longer identified as a shortage according to the Food and Drug Administration and American Society of Health-System Pharmacists.